Atorvastatin
- Generic Name
- Atorvastatin
- Brand Names
- Atorvaliq, Caduet, Lipitor, Lypqozet
- Drug Type
- Small Molecule
- Chemical Formula
- C33H35FN2O5
- CAS Number
- 134523-00-5
- Unique Ingredient Identifier
- A0JWA85V8F
- Background
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...
- Indication
Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...
- Associated Conditions
- Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
- Associated Therapies
- -
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2007-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2800
- Registration Number
- NCT00327418
- Locations
- 🇬🇧
Pfizer Investigational Site, Wishaw, United Kingdom
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
- Conditions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2007-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8600
- Registration Number
- NCT00327691
- Locations
Pfizer Investigational Site
Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 22
- Registration Number
- NCT00317967
- Locations
- 🇨🇦
University of Calgary, Faculty of Medicine, Calgary, Alberta, Canada
Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2010-02-23
- Lead Sponsor
- Kowa Research Europe
- Target Recruit Count
- 418
- Registration Number
- NCT00309751
- Locations
- 🇳🇱
Andromed Eindhoven, Eindhoven, Netherlands
🇳🇱Andromed Nijmegen, Nijmegen, Netherlands
🇩🇰CCBR Aalborg, Aalborg, Denmark
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
- Conditions
- Interventions
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- Abbott
- Target Recruit Count
- 613
- Registration Number
- NCT00300469
- Locations
- 🇺🇸
Global Medical Information, North Chicago, Illinois, United States
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2011-09-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 353
- Registration Number
- NCT00296374
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
🇦🇷Reasearch Site, La Plata, Argentina
🇭🇺Research site, Gyula, Hungary
Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
- Conditions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2011-06-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 237
- Registration Number
- NCT00296400
- Locations
- 🇿🇦
Research Site, Pretoria, South Africa
Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
- Conditions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1160
- Registration Number
- NCT00296387
- Locations
- 🇪🇸
Research site, Madrid, Spain
🇹🇳Research Site, Tunis, Tunisia
Statin Treatment in Patients With Asthma
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2015-09-16
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 10
- Registration Number
- NCT00292201
- Locations
- 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
- Conditions
- Interventions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2340
- Registration Number
- NCT00289900
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.